Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BPMC – Blueprint Medicines Corporation

Blueprint Medicines Corporation
BPMC
$128.23
Name : Blueprint Medicines Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $8,292,133,888.00
EPSttm : -2.51
finviz dynamic chart for BPMC
Blueprint Medicines Corporation
$128.23
0.09%
$0.12

Float Short %

5.02

Margin Of Safety %

Put/Call OI Ratio

1.32

EPS Next Q Diff

0.45

EPS Last/This Y

0.63

EPS This/Next Y

1.5

Price

128.13

Target Price

130.6

Analyst Recom

2.9

Performance Q

42.77

Relative Volume

0.99

Beta

0.88

Ticker: BPMC




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02BPMC127.780.701.1530394
2025-06-03BPMC127.640.833.9435789
2025-06-04BPMC128.060.952.9238138
2025-06-05BPMC128.251.001.5439153
2025-06-06BPMC127.81.021.4139010
2025-06-09BPMC127.921.020.8139053
2025-06-10BPMC127.951.021.3639204
2025-06-11BPMC127.971.020.2039282
2025-06-12BPMC128.241.015.4539471
2025-06-13BPMC127.991.014.6439482
2025-06-16BPMC128.251.011.9239470
2025-06-17BPMC128.271.0164.6039529
2025-06-18BPMC128.071.034.2739905
2025-06-20BPMC128.161.037.7439898
2025-06-23BPMC128.421.2352.0532459
2025-06-24BPMC128.271.3112.0633704
2025-06-25BPMC128.241.328.6733890
2025-06-26BPMC128.11.325.3833933
2025-06-27BPMC128.121.328.9233981
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02BPMC127.7536.45.8-0.44
2025-06-03BPMC127.6036.421.9-0.44
2025-06-04BPMC128.0936.421.6-0.44
2025-06-05BPMC127.9033.221.9-0.44
2025-06-06BPMC127.8233.221.8-0.44
2025-06-09BPMC127.9733.221.7-0.44
2025-06-10BPMC127.9733.221.8-0.44
2025-06-11BPMC127.9533.221.8-0.44
2025-06-12BPMC128.2133.221.7-0.44
2025-06-13BPMC127.9933.221.9-0.44
2025-06-16BPMC128.2833.221.6-0.44
2025-06-17BPMC128.2633.221.8-0.44
2025-06-18BPMC128.1233.221.9-0.44
2025-06-20BPMC128.2033.221.8-0.44
2025-06-23BPMC128.4033.221.7-0.44
2025-06-24BPMC128.2733.221.9-0.44
2025-06-25BPMC128.2933.221.8-0.44
2025-06-26BPMC128.1233.221.9-0.44
2025-06-27BPMC128.1333.221.8-0.44
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02BPMC-5.913.709.11
2025-06-03BPMC-5.823.709.11
2025-06-04BPMC-5.753.709.11
2025-06-05BPMC-5.853.709.11
2025-06-06BPMC-5.853.709.11
2025-06-09BPMC-5.853.699.11
2025-06-10BPMC-5.853.699.11
2025-06-11BPMC-5.853.699.78
2025-06-12BPMC-5.843.699.77
2025-06-13BPMC-5.843.699.77
2025-06-16BPMC-5.843.949.77
2025-06-18BPMC-5.773.949.77
2025-06-20BPMC-5.773.949.77
2025-06-23BPMC-5.123.749.77
2025-06-24BPMC-5.123.749.77
2025-06-25BPMC-5.123.749.77
2025-06-26BPMC-5.123.745.02
2025-06-27BPMC-5.123.745.02
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.74

Avg. EPS Est. Current Quarter

-0.53

Avg. EPS Est. Next Quarter

-0.29

Insider Transactions

-5.12

Institutional Transactions

3.74

Beta

0.88

Average Sales Estimate Current Quarter

171

Average Sales Estimate Next Quarter

191

Fair Value

Quality Score

47

Growth Score

56

Sentiment Score

80

Actual DrawDown %

0.3

Max Drawdown 5-Year %

-69.5

Target Price

130.6

P/E

Forward P/E

139.48

PEG

P/S

14.74

P/B

24.18

P/Free Cash Flow

EPS

-2.46

Average EPS Est. Cur. Y​

-0.44

EPS Next Y. (Est.)

1.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-27.7

Relative Volume

0.99

Return on Equity vs Sector %

-69.4

Return on Equity vs Industry %

-51.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

21.8
Blueprint Medicines Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 682
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
stock quote shares BPMC – Blueprint Medicines Corporation Stock Price stock today
news today BPMC – Blueprint Medicines Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch BPMC – Blueprint Medicines Corporation yahoo finance google finance
stock history BPMC – Blueprint Medicines Corporation invest stock market
stock prices BPMC premarket after hours
ticker BPMC fair value insiders trading